Abstract:Background: Primary biliary cholangitis (PBC) is characterized by nonsuppurative destructive cholangitis and is thought to be an autoimmune disorder. Currently, ursodeoxycholic acid (UDCA) is the only FDA approved first line therapy for PBC, but up to nearly one-third of patients do not achieve a complete response to this treatment. Adaptive immune cells, including T cells and B cells, have been found in the portal tracts and the bile duct epithelium and play a role in the pathogenesis of PBC, but the importance of these cells for evaluating the therapeutic response to UDCA in PBC has not yet been studied. Methods: In this study, we collected liver puncture biopsy specimens from 34 matched patients with PBC before and after UDCA treatment and investigated the relationship between the infiltration of adaptive immune cells and the treatment response to UDCA. The extent of immune cell infiltration was determined by immunohistochemical analysis. Responses were defined based on Paris-I criteria Results: After 1 year of treatment, 25/34 patients responded to UDCA treatment according to Paris-I criteria (responders), and 9/34 patients were nonresponders. Immunohistochemical analysis showed that UDCA responders exhibited significantly less CD4+ T cell infiltration after UDCA treatment than before (50.4 7.5/HPF vs 30.0 +/- 7.9/HPF, P = 0.002). In contrast, UDCA nonresponders exhibited significantly more CD4+ T cell infiltration after UDCA treatment than before (32.2 +/- 8.0/HPF vs 75.0 +/- 13.9/HPF, P = 0.045). Moreover, patients who exhibited a reduction in CD4+ T cell infiltration after UDCA treatment had a higher response rate than those that exhibited an increase in CD4+ T cell infiltration (85.7 % vs 53.8 %, P = 0.041). However, CD3+ T cell, CD8+ T cell, and CD20+ B cell infiltration was not significantly different before and after treatment in either UDCA responders or nonresponders. Furthermore, we found that the number of infiltrating T-bet+ Th1 cells was much lower after UDCA treatment than before in responders (10.5 +/- 5.7/HPF vs. 5.16 +/- 4.0/HPF, P = 0.0214) but much higher in nonresponders after treatment than before (1.89 +/- 1.2/HPF vs. 12.3 +/- 5.4/HPF, P = 0.043). However, there was no difference in the extent of GATA3+ Th2 or FOXP3+ Treg infiltration before and after treatment in either UDCA responders or nonresponders. Conclusion: Collectively, our results suggest that a decrease in the number of liver-infiltrating CD4+ Th1 cells is associated with a good response of PBC patients to UDCA treatment. Immunohistochemical analysis of CD4 and T-bet in PBC liver specimens may be a potential approach for evaluating the therapeutic response to UDCA.

5-Aza-2-deoxycytidine alleviates the progression of primary biliary cholangitis by suppressing the FoxP3 methylation and promoting the Treg/Th17 balance

Chemokine (C-X-C motif) ligand 13 promotes intrahepatic chemokine (C-X-C motif) receptor 5+ lymphocyte homing and aberrant B-cell immune responses in primary biliary cirrhosis.

Regulatory T Cells with a Defect in Inhibition on Co-Stimulation Deteriorated Primary Biliary Cholangitis

Therapeutic Potential of The Low-dose IL-2 Through Targeting the Th17/Treg Axis in Primary Biliary Cholangitis Mice

Successful immunotherapy of autoimmune cholangitis by adoptive transfer of forkhead box protein 3(+) regulatory T cells.

IL-17A produced by invariant natural killer T cells and CD3(+)CD56(+)alpha Galcer-CD1d tetramer(-) T cells promote liver fibrosis in patients with primary biliary cholangitis

IL-17A produced by invariant natural killer T cells and CD3+CD56+αGalcer-CD1d tetramer– T cells promote liver fibrosis in patients with primary biliary cholangitis

Effect of Allogeneic Bone Marrow–derived Mesenchymal Stem Cells Transplantation in a Polyi:C-Induced Primary Biliary Cirrhosis Mouse Model

Decreased Infiltration of CD4+ Th1 Cells Indicates a Good Response to Ursodeoxycholic Acid (UDCA) in Primary Biliary Cholangitis.

5-Aza-2'-deoxycytidine may enhance the frequency of T regulatory cells from CD4+ naïve T cells isolated from the peripheral blood of patients with chronic HBV infection

Single-cell RNA sequencing reveals the pro-inflammatory roles of liver-resident Th1-like cells in primary biliary cholangitis

Ursodeoxycholic acid impairs liver‐infiltrating T‐cell chemotaxis through IFN‐γ and CX3CL1 production in primary biliary cholangitis

Advances in the Treatment of Primary Biliary Cholangitis

Bile acid receptor agonists in primary biliary cholangitis: Regulation of the cholangiocyte secretome and downstream T cell differentiation

An enhanced level of LAMP-2A participates in CD4+T cell hyperactivity in patients with primary biliary cholangitis

Dysregulation of Peritoneal Cavity B1a Cells and Murine Primary Biliary Cholangitis

New Treatment Paradigms in Primary Biliary Cholangitis

The Proinflammatory Cytokines IL-18, IL-21, and IFN-γ Differentially Regulate Liver Inflammation and Anti-Mitochondrial Antibody Level in a Murine Model of Primary Biliary Cholangitis

Cholangiocytes-Specific Deletion of Sphingosine-1-phospholipid Receptor 1 Attenuate Cholestasis Induced Liver Injury and Fibrosis

Resistance to activation-induced cell death and elevated FLIP L expression of CD4+ T cells in a polyI:C-induced primary biliary cirrhosis mouse model

Anti-drug Antibodies Against a Novel Humanized Anti-CD20 Antibody Impair Its Therapeutic Effect on Primary Biliary Cholangitis in Human CD20- and FcγR-Expressing Mice